The role of pet in breast cancer: FDG and future directions

Seminars in Breast Disease

Volumn 5, Issue 3, 2002, Pages 116-127

  Eubank, William B ^b   Mankoff, David A ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Puget Sound VA Health Care System   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; FLUORODEOXYGLUCOSE F 18; GLUCOSE; TRACER;

AXILLARY LYMPH NODE; BONE METASTASIS; BONE SCINTISCANNING; BREAST CANCER; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; GLUCOSE METABOLISM; HUMAN; INTERMETHOD COMPARISON; LYMPH NODE METASTASIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY;

EID: 0036761208     PISSN: 10924450     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Muehllehnec G, Karp JS: Positron emission tomography imaging-Technical considerations. Semin Nucl Med 16:35-50, 1986
2. Hoffman EJ, van der Stee M, Ricci AR, et al: Prospects for both precision aud accuracy in positron emission tomography. Ann Neurol 15:S25-S34, 1984
3. Eary JF, Mankoff DA: Tumor metabolic rates in sarcoma using FDG PET. J Nucl Med 39:250-254, 1998
4. Warburg OH, Dickens F: The Metabolism of Tumours. New York, Richard R. Smith, 1931
5. Spence AM, Muzi M, Graham MM, et al: Glucose metabolism in human malignant gliomas measured quantitatively with PET, 1-[C-11]-glucose and FDG: Analysis of the FDG lumped constant. J Nucl Med 39:440-448, 1998
6. Wahl RL, Cody RL, Hutchins GD, et al: Primary and metaslatic breast carcinoma: Initial clinical evaluation with PET with radiolabeled glucose antigen 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 179:165-770, 1991.
7. Nieweg OE, Kim EE, Wong WH, et al: Positron emission tomography with [fluoriue-18]-deoxyglucose in the detection and signaling of breast cancer. Cancer 71:3920-3925, 1993
8. 18F]-fluoro-D-glucose uptake in locally advanced breast cancers. Eur J Surg Oncol 21:280-283, 1995
9. Tse NY, Hoh CK, Hawkins RA, et al: The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease. Ann Surg 216:27-34, 1992
10. Adler LP, Crowe JP, Al-Kaisi NK, et al: Evaluation of breast masses and axillary lymph nodes with [F-18]-2-deoxy-2- fluoro-D-glucose PET. Radiology 187:743-750, 1993
11. Hoh CK, Hawkins RA, Claspy JA, et al: Cancer detection with whole-body PET using 2-[F-18]-fluoro-2-deoxy-D-glucose. J Comput Assist Tomogr 17:582-589, 1993
12. Avril N, Dose J, Janicke F, et al: Metabolic characterization of breast tumors with positron emission tomography using [F-18]-fluorodeoxyglucose. J Clin Oncol 14:1848-1857, 1996
13. Avril N, Rose CA, Schelling M, et al: Breast imaging with positron emission tomography and [fluorine-18]-fluorodeoxyglucose: Use and limitations. J Clin Oncol 18:3495-3502, 2000
14. Schirrmeister H, Kuhn T, Guhlmann A, et al: [F-18]-2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: Comparison with the standard staging procedures. Eur J Nucl Med 28:351-858, 2001
15. Scheidhauer K, Scharl A, Pietrzyk U, et al: Qualitative [18F]-FDG positron emission tomography in primary breast cancer: Clinical relevance and practicability. Eur J Nucl Med 23:618-623, 1996
16. Parker SH, Jobe WE: Large-core breast biopsy offers reliable diagnosis. Diagn Imaging 12:90-97, 1990
17. Orel SG, Schnall MD, Powell CM, et al: Staging of suspected breast cancer: Effect of MR imaging and MR-guided biopsy. Radiology 196:115-122, 1995
18. 18F]-fluorodeoxyglucose uptake and positron histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: A preliminary observation. Eur J Nucl Med 25:1429-1434, 1998
19. 18F]fluoro-D-glucose. Cancer 82:2227- 2234, 1998
20. 18F-FDG PET: Histologic and immunohistochemical tissue analysis. J Nucl Med 42:9-16, 2001
21. 18F]-fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 20:379-387, 2002
22. Mankkoff DA, Dunnwald LK, Gralow JR, et al: Blood flow and metabolism in locally advanced breast cancer (LABC): Relationship to response to therapy. J Nucl Med 43:500-509, 2002
23. Dehdashti F, Mortimer NJE, Siegel BA, et al: Positron tomographic assessment of estrogen receptors in breast cancer: Comparison with FDG-PET and in vitro receptors assays. J Nucl Med 36:1766-1774, 1995
24. Crippa F, Agresti R, Segreni E, et al: Prospective evaluation of [fluorine-18]-FDG PET in presurgical staging of the axilla in breast cancer. J Nucl Med 39:4-8, 1998
25. Mankoff DA, Dehdashti F, Shields AF: Characterizing tumors using metabolic imaging: PET imaging of cellular proliferation and steroid receptors. Neoplasia 2:71-88, 2000
26. 18]-fluoromisonidazole: A pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 36:417-428, 1996
27. Adler LP, Faulhalber PF, Schnur KC, et al: Axillary lymph node metastases: Screening with [F-18]-2-deoxy-2-fluoro-D-glucose (FDG) PET. Radiology 203:323-327, 1997
28. Utech CI, Young CS, Winter PF: Prospective evaluation of [fluorine-18]-fluorodeoxyglucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry. Eur J Nucl Med 23:1588-1593, 1996
29. Avril N, Dose J, Janicke F, et al: Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-[fluorine-18]-fluoro-2-deoxy-D-glucose. J Natl Cancer Inst 88:1204-1209, 1996
30. Smith IC, Ogston KN, Whitford D, et al: Staging of the axilla in breast cancer: Accurate in vivo assessment using positron emission tomography with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose. Ann Surg 228:220-227, 1998
31. Greco M, Crippa F, Agresti R, et al: Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucosepositron emission tomography: Clinical evaluation and alternative management. J Natl Cancer Inst 93:630-635, 2001
32. Silverstein MJ, Gierson ED, Waisman JR, et al: Axillary lymph node dissection for T1a breast carcinoma. Is it indicated? Cancer 73:664-667, 1994
33. Yeatman TJ, Cox CE: The significance of breast cancer lymph node micrometastases. Surg Oncol Clin N Am 8:481-496, 1999
34. Albertini JJ, Lyman GH, Cox C, et al: Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA 276:1818-1822, 1996
35. Wagner JD, Schauwecker D, Davidson D, et al: Prospective study of fluorodeoxyglucose-positron, emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy. J Clin Oncol 17:1508-1515, 1999
36. Wojcik C Yahonda A, McFarlane D, et al: Economic analysis of sentinel-node surgery versus preoperative FDG-PET in the management of patients with intermediate thickness cutaneous melanomas. J Nucl Med 38:34P, 1997 (abstr 120)
37. Eubank WB, Mankoff DA, Schmiedl UP, et al: Imaging of oncologic patients: Benefit of combined CT and [F-18]-fluorodeoxyglucose positron emission tomography scan interpretation in the diagnosis of malignancy. AJR Am J Roentgenol 171:1103-1110, 1998
38. Katz A, Strom EA, Buchholz TA, et al: Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: Implications for postoperative irradiation. J Clin Oncol 18:2817-2827, 2000
39. Hathaway PB, Mankoff DA, Maravilla KR, et al: The value of combined FDG-PET and magnetic resonance imaging in the evaluation of suspected recurrent local-regional breast cancer: Preliminary experience. Radiology 210:807-814, 1998
40. Donegan WL: The influence of untreated internal mammary metastases upon the course of mammary cancer. Cancer 39: 533-538, 1977
41. Cody HS III, Urban JA: Internal mammary node status: A major prognosticator in axillary node-negative breast cancer. Ann Surg Oncol 2:32-37, 1995
42. Sugg SL, Ferguson DJ, Posner MC, et al: Should internal mammary nodes be sampled in the sentinel lymph node era? Ann Surg Oncol 7:188-192, 2000
43. Bellon JR, Mankoff DA, Eubank WB, et al: Evaluation of the internal mammary lymph node chain by PET in locally advanced breast cancer. J Nucl Med 41:145P, 2000 (abstr 574)
44. Bernstein V, Jones A, Mankoff DA, et al: Assessment of internal mammary lymph nodes by fluorodeoxyglucose positron emission (FDG PET) in medial hemisphere breast cancer. J Nucl Med 41:289P, 2000 (abstr 1206)
45. Vansteenkiste JF, Stroobants SG, De Leyn PR, et al: Lymph node signaling in non-small-cell lung cancer with FDG-PET scan: A prospective study on 690 lymph node stations from 68 patients. J Clin Oncol 16:2142-2149, 1998
46. Scott WJ, Gobar LS, Terry JD, et al: Mediastinal lymph node staging of non-small-cell lung cancer: A prospective comparison of computed tomography and positron emission tomography. J Thorac Cardiovasc Surg 111:642-648, 1996
47. 18Fluorodeoxyglucose positron emission tonmgraphy to detect mediastinal or internal mammary metastases in breast cancer. J Clin Oncol 19:3516-3523, 2001
48. Moon DH, Maddahi J, Silverman DHS, et al: Accuracy of whole-body [fluorine-18]-FDG PET for the detection of recurrent or metastatic breast carcinoma. J Nucl Med 39:431-435, 1998
49. 18fluoro-deoxyglucose positron emission tomography in the staging of recurrent breast carcinoma. Anticancer Res 17:1687-1692, 1997
50. Lonneux M, Borbath I, Berliere M, et al: The place of wholebody PET FDG for the diagnosis of distant recurrence of breast cancer. Clin Positron Imaging 3:45-49, 2000
51. Eubank WB, Mankoff DA, Vesselle HJ, et al: Detection of locoregional and distant recurrences in breast cancer patients by using FDG PET. Radiographics 22:5-17, 2002
52. 18F-FDG PET and couventional imaging for predicting outcome in previously treated breast cancer patients. J Nucl Med 43: 325-329, 2002
53. Nielsen OS, Munro AJ, Tannock IF: Bone metastases: Pathophysiology and management policy. J Clin Oncol 9:509-524, 1991
54. 18FDG PET: Differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol 16:3375-3379, 1998
55. Machiavelli MR, Romero AO, Pérez JE, et al: Prognostic significance of pathological response of primary minor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma. Cancer J Sci Am 4:125-131, 1998
56. Helvie MA, Joynt LK, Cody RL, et al: Locally advanced breast carcinoma: Accuracy of mammography versus clinical examination in the prediction of residual disease alter chemotherapy. Radiology 198:327-332, 1996
57. Wahl RL, Zasadny K, Helvie MA, et al: Metabolic monitoring of breast cancer chemotohormonotherapy using positron emission tomography: Initial evaluation. J Clin Oncol 11:2101-2111, 1993
58. Bassa P, Kim EE, Inoue T, et al: Evaluation of preoperative chemotherapy using PET with [fluorine-18]-fluorodeoxyglucose in breast cancer. J Nucl Med 37:931-938, 1996
59. Jansson T, Westlin J, Ahlstrom H, et al: Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: A method for early therapy evaluation? J Clin Oncol 13:1470-1477, 1995
60. 18F]-fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 18:1689-1695, 2000
61. 18F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 18:1676-1688, 2000
62. Jain RK: Haemodynamic and transport barriers to the treatment of solid tumors. Int J Radiat Biol 60:85-100, 1991
63. 18F]-fluorodeoxyglncose (FDG) positron emission tomography (PET) in the early assessment of response to chemotherapy in metastati breast cancer patients. Clin Breast Cancer 1:156-161, 2000
64. Stafford SE, Gralow JR, Schubert EK, et al: Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy. Acad Radiol 9:913-921, 2002
65. Schneider JA, Divgi CR, Scott AM, et al: Flare on bone scintigraphy following toxicol chemotherapy for metastatic breast cancer. J Nucl Med 35:1748-1752, 1994
66. Mortimer JE, Dehdashti F, Siegel BA, et al: Metabolic flare: Indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol 19:2797-2803, 2001
67. Shields AF, Mankoff DA, Link JM, et al: [Carbon-11]-thymidine and FDG to measure therapy response. J Nucl Med 39: 1757-1762, 1998
68. Hull DF III, Clark GM, Osborne CK, et al: Multiple estrogen receptor assays in human breast cancer. Cancer Res 43:413-416, 1983
69. Kiesewetrer DO, Kilbourn MR, Landvatter SW, et al: Preparation of four fluorine-18-labeled estrogens and their selective uptakes in target tissue of immature rats. J Nucl Med 25: 1212-1221, 1984
70. Mintun MA, Welch MJ, Siegel BA, et al: Breast cancer: PET imaging of estrogen receptors. Radiology 169:45-48, 1988
71. McGaire AH, Dehdashti F, Siegel BA, et al: Positron tomographic assessment of 16alpha-[F-18]-fiuoro-17beta-estradiol uptake in metastatic breast carcinoma. J Nucl Med 32: 1526-1531, 1991
72. 18F]-fluoroestradiol radiation dosimetry in human PET studies. J Nucl Med 42:679-684, 2001
73. Dehdashti F, Flanagan FL, Mortimer JE, et al: Positron emission tomographic assessmemt of "metabolic flare" to predict response of metastatic breast: cancer to antiestrogen therapy. Eur J Nucl Med 26:51-56, 1999
74. Reiner A, Neumeister B, Spona J, et al: Immunocytochemical localization of estrogen and progesterone receptor and prognosis in human primary breast cancer. Cancer Res 50:7057-7061, 1990
75. Mankoff DA, Peterson LM, Tewson TJ, et al: Non-invasive PET imaging of ER expression in breast cancer: Sex steroid binding protein (SBP or SHBG) interaction and ER expression heterogeneity. Proc Am Assoc Cancer Res 42:6, 2001 (abstr 32)